Successful Chemotherapy for Recurrent Malignant Oligodendroglioma

Overview

Journal Ann Neurol

Specialty Neurology

Date 1988 Apr 1

PMID 3382171

Citations 86

Authors

J G Cairncross

D R Macdonald

Affiliations

Soon will be listed here.

Abstract

Eight consecutive patients with recurrent malignant oligodendroglioma were treated with systemic chemotherapy. Six patients received a combination of procarbazine, lomustine (CCNU), and vincristine; 1 received carmustine (BCNU), and 1 diaziquone. All responded by clinical and computed tomographic scan criteria. One patient had a complete response for 78 weeks, and 7 patients had unequivocal partial responses lasting 30+ to 68+ weeks. Two partial responders had complete control of systemic metastases. Malignant oligodendroglioma is a uniquely chemosensitive glial tumor.

Citing Articles

Management of Low-Grade Gliomas.

Diaz M, Pan P Cancer J. 2025; 31(1).

PMID: 39841424 PMC: 11801446. DOI: 10.1097/PPO.0000000000000760.

Genomic alterations of oligodendrogliomas at distant recurrence.

Liu G, Bu C, Guo G, Zhang Z, Sheng Z, Deng K Cancer Med. 2023; 12(16):17171-17183.

PMID: 37533228 PMC: 10501240. DOI: 10.1002/cam4.6327.

Brain Plasticity Profiling as a Key Support to Therapeutic Decision-Making in Low-Grade Glioma Oncological Strategies.

Ng S, Duffau H Cancers (Basel). 2023; 15(14).

PMID: 37509359 PMC: 10378506. DOI: 10.3390/cancers15143698.

Therapies for IDH-Mutant Gliomas.

Nasany R, de la Fuente M Curr Neurol Neurosci Rep. 2023; 23(5):225-233.

PMID: 37060388 PMC: 10182950. DOI: 10.1007/s11910-023-01265-3.

A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma.

Oberheim Bush N, Young J, Zhang Y, Dalle Ore C, Molinaro A, Taylor J J Neurooncol. 2021; 153(3):447-454.

PMID: 34125374 PMC: 8279971. DOI: 10.1007/s11060-021-03781-z.